• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study.

作者信息

Suen H, Brown R, Yang S, Ho P J, Gibson J, Joshua D

机构信息

Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

出版信息

Leukemia. 2015 Jul;29(7):1621-2. doi: 10.1038/leu.2015.104. Epub 2015 May 19.

DOI:10.1038/leu.2015.104
PMID:25987102
Abstract
摘要

相似文献

1
The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study.在一项1期研究中，PD - 1抑制剂用于多发性骨髓瘤的免疫检查点阻断治疗失败。
Leukemia. 2015 Jul;29(7):1621-2. doi: 10.1038/leu.2015.104. Epub 2015 May 19.
2
Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.靶向浆细胞样树突状细胞与T细胞、自然杀伤细胞和多发性骨髓瘤细胞相互作用中的PD1-PDL1免疫检查点。
Leukemia. 2015 Jun;29(6):1441-4. doi: 10.1038/leu.2015.11. Epub 2015 Jan 30.
3
Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?旁观者记忆 T 细胞与 IMiD/检查点疗法在多发性骨髓瘤中的应用：一场危险的探戈？
Front Immunol. 2021 Feb 15;12:636375. doi: 10.3389/fimmu.2021.636375. eCollection 2021.
4
Role of Immune Therapies for Myeloma.免疫疗法在骨髓瘤中的作用。
J Natl Compr Canc Netw. 2015 Nov;13(11):1440-7. doi: 10.6004/jnccn.2015.0168.
5
New B7 Family Checkpoints in Human Cancers.人类癌症中的新型B7家族检查点
Mol Cancer Ther. 2017 Jul;16(7):1203-1211. doi: 10.1158/1535-7163.MCT-16-0761.
6
PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.恶性淋巴瘤中的PD-1-PD-L1免疫检查点阻断
Ann Hematol. 2018 Feb;97(2):229-237. doi: 10.1007/s00277-017-3176-6. Epub 2017 Nov 11.
7
Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma.PD-1/PD-L1 抑制剂在多发性骨髓瘤中的应用的承诺和陷阱。
Front Immunol. 2018 Nov 27;9:2749. doi: 10.3389/fimmu.2018.02749. eCollection 2018.
8
Programmed death-1 checkpoint blockade in acute myeloid leukemia.急性髓系白血病中的程序性死亡-1检查点阻断
Expert Opin Biol Ther. 2015;15(8):1191-203. doi: 10.1517/14712598.2015.1051028. Epub 2015 Jun 3.
9
Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.T细胞免疫效应分子与检查点分子的比值作为弥漫性大B细胞淋巴瘤的预后生物标志物：一项基于人群的研究
Lancet Haematol. 2015 Oct;2(10):e445-55. doi: 10.1016/S2352-3026(15)00150-7. Epub 2015 Oct 1.
10
Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic.针对 COVID-19 大流行，对癌症患者的细胞免疫组进行研究。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-002087.

引用本文的文献

1
Expanded and activated marrow-infiltrating lymphocytes exhibit potent antimyeloma activity against autologous multiple myeloma cells.扩增并活化的骨髓浸润淋巴细胞对自体多发性骨髓瘤细胞表现出强大的抗骨髓瘤活性。
Transl Oncol. 2025 Jul 24;60:102475. doi: 10.1016/j.tranon.2025.102475.
2
Applying metabolic control strategies to engineered T cell cancer therapies.将代谢控制策略应用于工程化T细胞癌症治疗。
Metab Eng. 2024 Nov;86:250-261. doi: 10.1016/j.ymben.2024.10.009. Epub 2024 Oct 25.
3
Identifying ADGRG1 as a specific marker for tumor-reactive T cells in acute myeloid leukemia.

本文引用的文献

1
Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.靶向浆细胞样树突状细胞与T细胞、自然杀伤细胞和多发性骨髓瘤细胞相互作用中的PD1-PDL1免疫检查点。
Leukemia. 2015 Jun;29(6):1441-4. doi: 10.1038/leu.2015.11. Epub 2015 Jan 30.
2
Genetic basis for clinical response to CTLA-4 blockade in melanoma.黑色素瘤中CTLA-4阻断临床反应的遗传基础。
N Engl J Med. 2014 Dec 4;371(23):2189-2199. doi: 10.1056/NEJMoa1406498. Epub 2014 Nov 19.
3
Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance.
鉴定ADGRG1作为急性髓系白血病中肿瘤反应性T细胞的特异性标志物。
Exp Hematol Oncol. 2024 Sep 6;13(1):92. doi: 10.1186/s40164-024-00560-0.
4
The loss of neoantigens is an important reason for immune escape in multiple myeloma patients with high intratumor heterogeneity.肿瘤内异质性高的多发性骨髓瘤患者发生免疫逃逸的一个重要原因是新抗原丢失。
Cancer Med. 2023 Dec;12(24):21651-21665. doi: 10.1002/cam4.6721. Epub 2023 Nov 15.
5
Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing.通过常规配对的肿瘤和正常测序增强血液系统恶性肿瘤的临床评估。
Nat Commun. 2023 Oct 28;14(1):6895. doi: 10.1038/s41467-023-42585-9.
6
Single-cell analysis of the CD8 T-cell compartment in multiple myeloma reveals disease specific changes are chiefly restricted to a CD69 subset suggesting potent cytotoxic effectors exist within the tumor bed.对多发性骨髓瘤 CD8 T 细胞区室进行单细胞分析表明，疾病特异性变化主要局限于 CD69 亚群，这表明在肿瘤床内存在有效的细胞毒性效应器。
Haematologica. 2024 Apr 1;109(4):1220-1232. doi: 10.3324/haematol.2023.283062.
7
CD73 Dysregulates Monocyte Anti-Tumor Activity in Multiple Myeloma.CD73失调多发性骨髓瘤中单核细胞的抗肿瘤活性。
Cancer Manag Res. 2023 Jul 19;15:729-738. doi: 10.2147/CMAR.S411547. eCollection 2023.
8
Antibody Surface Profiling Identifies Glycoforms in Multiple Myeloma as Targets for Immunotherapy: From Antibody Derivatives to Mimetic Peptides for Killing Tumor Cells.抗体表面分析确定多发性骨髓瘤中的糖型为免疫治疗靶点：从抗体衍生物到用于杀伤肿瘤细胞的模拟肽
Cancers (Basel). 2023 Mar 23;15(7):1934. doi: 10.3390/cancers15071934.
9
Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors.在骨髓瘤患者中，PD-1 和 CTLA-4 检查点的异常表达在诊断时更为明显：对进展时间和治疗性检查点抑制剂反应的影响。
Int J Mol Sci. 2023 Mar 17;24(6):5730. doi: 10.3390/ijms24065730.
10
Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma.治疗初发多发性骨髓瘤患者骨髓克隆性扩增 T 细胞的免疫表型和靶抗原。
Cancer Immunol Res. 2022 Nov 2;10(11):1407-1419. doi: 10.1158/2326-6066.CIR-22-0434.
多发性骨髓瘤的长期生存与独特的免疫特征相关，包括增殖性细胞毒性 T 细胞克隆和有利的 Treg/Th17 平衡。
Blood Cancer J. 2013 Sep 13;3(9):e148. doi: 10.1038/bcj.2013.34.
4
Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma.沙利度胺治疗多发性骨髓瘤患者后可刺激具有预后意义的细胞毒性 T 细胞克隆。
Leuk Lymphoma. 2009 Nov;50(11):1860-4. doi: 10.3109/10428190903216804.
5
Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment.克隆性细胞毒性T细胞在骨髓瘤中扩增，并存在于CD8(+)CD57(+)CD28(-)亚群中。
Blood. 2001 Nov 1;98(9):2817-27. doi: 10.1182/blood.v98.9.2817.
6
Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts.克隆性扩增的CD28-CD8+ T细胞中端粒缩短，这意味着其复制历史与CD28+CD8+对应细胞不同。
J Immunol. 1996 May 15;156(10):3587-90.